Current Situation of Health Care in Women With HBV or HCV Infection

Sponsor
Ruijin Hospital
Study ID
NCT06579313
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.

Key Dates

Start date
Sep 1, 2024
Status verified
Aug 2024
Primary completion
Apr 30, 2025
Completion
Jul 31, 2025

Study Design

Enrollment
2,500 participants (estimated)

Arms

  • Arm: HBV cohort
    2000 HBsAg positive patients during 2016.7-2019.12
  • Arm: HCV cohort
    500 HCV Ab positive and HCV RNA positive patients during 2020.7-2023.12

Primary Outcome Measure

Treatment Rate in male in HBV cohort [ Time Frame: from July 2020 to December 2023 ]

Central Contacts

Related Studies